These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2754306)

  • 1. Transfusional iron overload in patients undergoing dialysis: treatment with erythropoietin and phlebotomy.
    McCarthy JT; Johnson WJ; Nixon DE; Jenson BM; Moyer TP
    J Lab Clin Med; 1989 Aug; 114(2):193-9. PubMed ID: 2754306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human erythropoietin and phlebotomy in the treatment of iron overload in chronic hemodialysis patients.
    Lazarus JM; Hakim RM; Newell J
    Am J Kidney Dis; 1990 Aug; 16(2):101-8. PubMed ID: 2382644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of a patient with end-stage renal disease, severe iron overload and ascites by weekly phlebotomy combined with recombinant human erythropoietin.
    Nomura S; Osawa G; Karai M
    Nephron; 1990; 55(2):210-3. PubMed ID: 2362636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic computed tomography for monitoring the iron status of haemodialysis patients with haemosiderosis treated with recombinant human erythropoietin.
    De Marchi S; Cecchin E
    Clin Sci (Lond); 1991 Jul; 81(1):113-21. PubMed ID: 1649718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity.
    Tarng DC; Huang TP
    Am J Nephrol; 1998; 18(1):1-8. PubMed ID: 9481432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct effect of deferoxamine on hemoglobin synthesis in patients on hemodialysis treated with recombinant human erythropoietin.
    Romero R; Novoa D; Otero S; Alonso MC; Alonso R; Arcocha V; Arza D; Lens XM; Sanchez-Guisande D
    Nephron; 1993; 63(2):164-7. PubMed ID: 8450906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human recombinant erythropoietin and phlebotomy in the treatment of iron overload in uremic patients.
    Chen KS; Leu ML; Huang CC
    Changgeng Yi Xue Za Zhi; 1995 Sep; 18(3):248-53. PubMed ID: 8521335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of pancreatic beta-cell function in hemochromatosis: combined treatment with recombinant human erythropoietin and phlebotomy.
    Inoue Y; Nakanishi K; Hiraga T; Okubo M; Murase T; Kosaka K; Miyakoshi S; Mutoh Y; Kobayashi T
    Am J Med Sci; 1997 Dec; 314(6):401-2. PubMed ID: 9413346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of iron overload with combination of recombinant human erythropoietin and phlebotomy].
    Nagafuji K; Shibuya T; Yanagida K; Okamura T; Nakamura M; Harada M; Niho Y; Yamano Y
    Rinsho Ketsueki; 1991 Jul; 32(7):791-5. PubMed ID: 1920844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction of serious iron overload in a chronic hemodialysis patient by recombinant human erythropoietin and removal of red blood cells: confirmation by follow-up liver biopsy.
    Onoyama K; Nakamura S; Yamamoto M; Kawadoko T; Nanishi F; Komoda T; Murai K; Fujishima M
    Nephron; 1990; 56(3):325-8. PubMed ID: 2077417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores.
    Hughes RT; Smith T; Hesp R; Hulme B; Dukes DC; Bending MB; Pearson J; Raja KB; Cotes PM; Pippard MJ
    Br J Haematol; 1992 Oct; 82(2):445-54. PubMed ID: 1419827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined recombinant human erythropoietin-blood letting strategy for treating anemia and iron overload in hemodialysis patients.
    Agroyannis B; Koutsicos D; Tzanatou-Exarchou H; Varsou-Papadimitriou E; Kapetanaki A; Yatzidis H
    Int J Artif Organs; 1991 Jul; 14(7):403-6. PubMed ID: 1889892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of nuclear magnetic resonance imaging in monitoring total body iron in hemodialysis patients with hemosiderosis treated with erythropoietin and phlebotomy.
    Chan PC; Liu P; Cronin C; Heathcote J; Uldall R
    Am J Kidney Dis; 1992 May; 19(5):484-9. PubMed ID: 1585939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction in liver iron in hemodialysis patients with transfusional iron overload by deferoxamine mesylate.
    Mossey RT; Wielopolski L; Bellucci AG; Wilkes BM; Chandra M
    Am J Kidney Dis; 1988 Jul; 12(1):40-4. PubMed ID: 3389353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Iron metabolism under rEPO therapy in patients on maintenance hemodialysis.
    Bergmann M; Grützmacher P; Heuser J; Kaltwasser JP
    Int J Artif Organs; 1990 Feb; 13(2):109-12. PubMed ID: 2347653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload.
    Panch SR; Yau YY; West K; Diggs K; Sweigart T; Leitman SF
    Transfusion; 2015 Mar; 55(3):611-22. PubMed ID: 25209879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Idiopathic hemochromatosis: serum ferritin concentrations during therapy by phlebotomy.
    Garry PJ; Saiki JH
    Clin Chem; 1982 Aug; 28(8):1806-8. PubMed ID: 7094303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.